Viktor Grünwald, Professor of Urologic Oncology at the University Hospital Essen, shared a post on LinkedIn:
”Biomarkers of ICI response in mRCC
In 45 tumor samples from ICI-treated mRCC patients, we examined 28 immunomodulatory markers (IHC, digital TMA analysis with QuPath) for their prediction of PFS.
Results
- Higher CD47 (phagocytosis checkpoint) → significantly longer PFS
- Higher CD20 (B-cell marker) → significantly longer PFS
- CD20 correlates with tumor-infiltrating immune cells and other checkpoints
Both markers appear to indicate a highly immunoinfiltrated but immunosuppressed TME – exactly the constellation that benefits most from ICI.
CD47 and CD20 could help to distinguish responders from non-responders and avoid unnecessary toxicity/costs.”
Title: Assessment of Tumor Microenvironment Inflammatory Biomarkers in Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
Authors: Jessica Schmitz, Manuel M. Vicente, Nikolaos Vasileiadis, David Christensen, Melanie Maulhardt, Markus A. Kuczyk, Hossein Tezval, Christopher Darr, Viktor Grünwald, Philipp Ivanyi, Jan H. Bräsen
Other Articles Featuring Viktor Grünwald On OncoDaily.